SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
“The unprecedented positive efficacy data we announced from the interim analysis of the TREK-DX study of eblasakimab in dupilumab-experienced AD patients in April was a fantastic achievement for ASLAN. Most of the 22 patients on eblasakimab achieved EASI-90 and vIGA of 0 or 1 after just 16 weeks of treatment - numbers that have not been seen in other biologics AD studies. These data give us strong confidence in eblasakimab’s potential to be a best-in-class treatment for AD patients even after they have had an inadequate response to dupilumab, a significant and underserved patient population with limited safe and long-term treatment options,” said Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals. “Discussions with potential partners on eblasakimab are progressing well and we look forward to the upcoming topline clinical readouts from FAST-AA, the Phase 2a, proof-of-concept study of farudodstat in alopecia areata, and TREK-DX in the second half of 2024.”
First quarter 2024 and recent clinical developments
First quarter and recent corporate updates
Anticipated upcoming milestones
First quarter 2024 financial highlights
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEETS (In US Dollars, other than shares or share data) | ||||||||
December 31, 2023 (audited) | March 31, 2024 (unaudited) | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 21,252,058 | $ | 18,396,364 | ||||
Other assets | 2,877,934 | 2,179,230 | ||||||
Total current assets | $ | 24,129,992 | $ | 20,575,594 | ||||
NON-CURRENT ASSETS | ||||||||
Investments in equity instrument at financial asset at fair value through other comprehensive income | 235,567 | 235,567 | ||||||
Property, plant and equipment | 29,268 | 23,074 | ||||||
Right-of-use assets | 229,982 | 153,320 | ||||||
Intangible assets | 1,716 | 686 | ||||||
Total non-current assets | 496,533 | 412,647 | ||||||
TOTAL ASSETS | $ | 24,626,525 | $ | 20,988,241 | ||||
LIABILITIES AND EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Trade payables | $ | 7,918,607 | $ | 9,656,228 | ||||
Other payables | 3,081,329 | 2,350,857 | ||||||
Lease liabilities - current | 226,187 | 150,243 | ||||||
Current borrowings | 1,800,387 | 7,165,572 | ||||||
Financial liabilities at fair value through profit or loss | 88,394 | 280,646 | ||||||
Total current liabilities | 13,114,904 | 19,603,546 | ||||||
NON-CURRENT LIABILITY | ||||||||
Long-term borrowings | 24,798,552 | 19,349,656 | ||||||
Total non-current liability | 24,798,552 | 19,349,656 | ||||||
Total liabilities | 37,913,456 | 38,953,202 | ||||||
EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY | ||||||||
Ordinary shares | 63,931,993 | 65,189,432 | ||||||
Capital surplus | 243,791,693 | 247,775,683 | ||||||
Accumulated deficits | (321,067,236 | ) | (330,986,695 | ) | ||||
Other reserves | 56,619 | 56,619 | ||||||
Total equity attributable to stockholders of the Company | (13,286,931 | ) | (17,964,961 | ) | ||||
Total equity/(capital deficiency) | (13,286,931 | ) | (17,964,961 | ) | ||||
TOTAL LIABILITIES AND EQUITY/(CAPITAL DEFICIENCY) | $ | 24,626,525 | $ | 20,988,241 | ||||
ASLAN Pharmaceuticals Limited CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In US Dollars, other than shares or share data) | ||||||||
For the Three Months Ended March 31 (unaudited) | ||||||||
2023 | 2024 | |||||||
OPERATING EXPENSES | ||||||||
General and administrative expenses | $ | (4,047,567 | ) | $ | (3,396,080 | ) | ||
Research and development expenses | (14,055,560 | ) | (5,895,078 | ) | ||||
Total operating expenses | (18,103,127 | ) | (9,291,158 | ) | ||||
LOSS FROM OPERATIONS | (18,103,127 | ) | (9,291,158 | ) | ||||
NON-OPERATING INCOME AND EXPENSES | ||||||||
Interest income | 324,547 | 1,740 | ||||||
Other income | 134 | 69 | ||||||
Other gains and losses | (240,875 | ) | 35,957 | |||||
Finance costs | (1,074,850 | ) | (666,066 | ) | ||||
Total non-operating income and expenses | (991,044 | ) | (628,300 | ) | ||||
Share in losses of associated company, accounted for using equity method | (11,533 | ) | — | |||||
LOSS BEFORE INCOME TAX | (19,105,704 | ) | (9,919,458 | ) | ||||
INCOME TAX EXPENSE | (6,593 | ) | — | |||||
NET LOSS FOR THE PERIOD | (19,112,297 | ) | (9,919,458 | ) | ||||
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD | $ | (19,112,297 | ) | $ | (9,919,458 | ) | ||
NET LOSS ATTRIBUTABLE TO: | ||||||||
Stockholders of the Company | $ | (19,112,297 | ) | $ | (9,919,458 | ) | ||
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO: | ||||||||
Stockholders of the Company | $ | (19,112,297 | ) | $ | (9,919,458 | ) | ||
LOSS PER ORDINARY SHARE | ||||||||
Basic and diluted | $ | (0.05 | ) | $ | (0.02 | ) | ||
LOSS PER EQUIVALENT ADS | ||||||||
Basic and diluted | $ | (1.29 | ) | $ | (0.53 | ) | ||
Weighted-average number of ordinary shares in the computation of basic loss per ordinary share | 370,707,916 | 466,761,105 | ||||||
Weighted-average number of ADS in the computation of basic loss per ADS | 14,828,317 | 18,670,444 | ||||||
Each ADS represents twenty-five ordinary shares
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the TREK-DX Phase 2 trial, with topline data expected at the end of 2024. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in Q3 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the ASLAN website or follow ASLAN on LinkedIn.
Forward looking statements
This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of the Company. These forward-looking statements may include, but are not limited to statements regarding the Company’s business strategy and clinical development plans; statements related to the safety and efficacy of eblasakimab and farudodstat, including interim results; the Company’s plans and expected timing with respect to clinical trials, clinical trial enrollment and clinical trial results for eblasakimab and farudodstat; the potential of eblasakimab as a first-in-class treatment for atopic dermatitis and of farudodstat as a first-in-class treatment for alopecia areata; the Company’s cash runway; and expectations regarding the terms of patents and ability to obtain and maintain intellectual property protection for product candidates. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; risks that future clinical trial results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials; clinical site activation rates or clinical trial enrollment rates that are lower than expected; the impact of health epidemics or pandemics, or geopolitical conflicts on the Company’s operations, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, other service providers and collaborators with whom the Company conducts business; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001- 38475), including the Company’s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 12, 2024. All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.
ASLAN Media and IR contacts
Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$0.60 |
Daily Volume: | 0 |
Market Cap: | US$1.700M |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB